Hoeiland Jesper 4

What Happened
Jesper Hoeiland, a director of Allarity Therapeutics, was reported as receiving 25,000 restricted stock units (RSUs) under the company's Amended and Restated 2021 Equity Incentive Plan. The Form 4 lists the transaction as an award/acquisition (Code A) for 25,000 shares at $0.00 per share (total reported cash consideration $0). A footnote states the RSUs were granted on January 28, 2026 and vested in full on the grant date, meaning the award converted to ownership immediately upon grant.

Key Details

• Reported transaction date on Form 4: 2026-01-07 (the filing’s footnote states grant date was 2026-01-28 and that the RSUs vested in full on the grant date).
• Transaction type/code: A (award/other acquisition).
• Quantity: 25,000 RSUs; price reported: $0.00 per share (no cash paid).
• Shares owned after transaction: not disclosed in the provided extract.
• Form 4 filed: 2026-05-11 (several months after the reported dates). The filing therefore appears late relative to the usual two-business-day Form 4 filing requirement.
• Footnote F1: RSUs granted under the 2021 Equity Incentive Plan vested in full on the grant date.
• The filing extract does not indicate any immediate sale, tax withholding transaction, or a 10b5-1 plan.

Context
RSUs are a form of compensation: a $0 per-share entry on Form 4 reflects issuance of equity rather than a market purchase or sale. Because these RSUs vested immediately, Hoeiland obtained current ownership of the shares rather than a contingent future right. Such compensation awards are routine for executives and directors and do not, by themselves, indicate insider buying or selling intent. Note that the Form 4 was filed months after the reported transaction, which reduces the timeliness of this disclosure for investors.